NDAORALTABLETPriority Review
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUNLENCA (lenacapavir sodium) is an oral small-molecule capsid inhibitor approved by the FDA in December 2022 for HIV treatment. It represents a novel mechanism of action in antiretroviral therapy, targeting a previously unexploited step in viral replication. The drug is indicated for treatment-experienced patients with HIV-1 resistant to multiple antiretroviral classes.
Peak15.0 years to LOE
Product is in peak commercial phase with strong Gilead backing; commercial teams are likely scaling to capture resistant-patient market segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Gilead Sciences is hiring 1 role related to this product
Worked on SUNLENCA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.